 Seres Therapeutics NASDAQ:MCRB was upgraded by investment analysts at ValuEngine from a hold rating to a buy rating in a research note issued on Tuesday, ValuEngine reports. Several other brokerages have also commented on MCRB. BidaskClub lowered Seres Therapeutics from a buy rating to a hold rating in a report on Saturday, July 18th. Oppenheimer ... 